Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Ezetimibe in Human Plasma and Pharmaceutical Formulations
- 23 March 2006
- journal article
- Published by Springer Science and Business Media LLC in Chromatographia
- Vol. 63 (7-8), 315-320
- https://doi.org/10.1365/s10337-006-0749-2
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage formsJournal of Pharmaceutical and Biomedical Analysis, 2005
- Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC–MS/MS with electrospray ionization: Assay development, validation and application to a clinical studyJournal of Pharmaceutical and Biomedical Analysis, 2005
- Pharmaceutical Applications of Liquid Chromatography Coupled with Mass Spectrometry (LC/MS)Journal of Liquid Chromatography & Related Technologies, 2005
- Ezetimibe: first in a new class of cholesterol absorption inhibitorsInternational Congress Series, 2004
- The Discovery of Ezetimibe: A View from Outside the ReceptorJournal of Medicinal Chemistry, 2003
- A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibeClinical Therapeutics, 2001
- Ezetimibe: a selective inhibitor of cholesterol absorptionEuropean Heart Journal Supplements, 2001